keyword
https://read.qxmd.com/read/38655143/ultrasensitive-psa-rethinking-post-surgical-management-for-node-positive-prostate-cancer
#1
JOURNAL ARTICLE
Jonathan A Aguiar, Eric V Li, Austin Ho, Richard Bennett, Yutai Li, Clayton Neill, Edward M Schaeffer, Hiten D Patel, Ashley E Ross
INTRODUCTION: Clinicians may offer patients with positive lymph nodes (pN1) and undetectable PSA following surgery for prostate cancer either observation or adjuvant therapy based on AUA, EAU, and NCCN guidelines considering standard PSA detection thresholds of <0.1ng/ml. Here we sought to investigate the outcomes of pN1 patients in the era of ultrasensitive PSA testing. METHODS: We queried the Northwestern Electronic Data Warehouse for patients with prostate cancer who were pN1 at radical prostatectomy and followed with ultrasensitive PSA...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38654626/the-added-value-of-prostate-magnetic-resonance-imaging-to-patient-selection
#2
JOURNAL ARTICLE
Erin M Jyo, Hyo-Chun Yoon, Bradford Burton
INTRODUCTION: There has been a rapid increase in the utilization of magnetic resonance imaging (MRI) for prostate cancer detection. The objective of this study was to measure the increase in utilization of MRI before prostate biopsy and the effects on the distribution of Prostate Imaging Reporting and Data System (PI-RAD) scores and Gleason grades over a 5-year interval in an integrated health system. METHODS: The authors conducted a retrospective analysis of prostate MRI studies prior to biopsy in the calendar years of 2017 and 2022...
April 24, 2024: Permanente Journal
https://read.qxmd.com/read/38652872/salvage-reirradiation-for-locally-recurrent-prostate-cancer-results-from-a-prospective-study-with-7-2-years-of-follow-up
#3
JOURNAL ARTICLE
Christian Ekanger, Svein Inge Helle, Lars Reisæter, Liv Bolstad Hysing, Rune Kvåle, Alfred Honoré, Karsten Gravdal, Sara Pilskog, Olav Dahl
PURPOSE: There are no well-established re-treatment options for local recurrence after primary curative radiation therapy for prostate cancer (PCa), as prospective studies with long-term follow-up are lacking. Here, we present results from a prospective study on focal salvage reirradiation with external-beam radiation therapy with a median follow-up of 7.2 years. MATERIALS AND METHODS: From 2013 to 2017, 38 patients with biopsy-proven locally recurrent PCa >2 years after previous treatment and absence of grade 2-3 toxicity from the first course of radiation were included...
April 23, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38636793/dietary-fiber-intake-and-risk-of-advanced-and-aggressive-forms-of-prostate-cancer-a-pooled-analysis-of-15-prospective-cohort-studies
#4
JOURNAL ARTICLE
Elkhansa Sidahmed, Stephen J Freedland, Molin Wang, Kana Wu, Demetrius Albanes, Matt Barnett, Piet A van den Brandt, Michael B Cook, Graham G Giles, Edward Giovannucci, Christopher A Haiman, Susanna C Larsson, Timothy J Key, Erikka Loftfield, Satu Männistö, Marjorie L McCullough, Roger L Milne, Marian L Neuhouser, Elizabeth A Platz, Aurora Perez-Cornago, Norie Sawada, Jeannette M Schenk, Rashmi Sinha, Shoichiro Tsugane, Kala Visvanathan, Ying Wang, Kami K White, Walter C Willett, Alicja Wolk, Regina G Ziegler, Jeanine M Genkinger, Stephanie A Smith-Warner
BACKGROUND: Evidence of an association between dietary fiber intake and risk of advanced and aggressive forms of prostate cancer (PC) and PC mortality is limited. OBJECTIVE: To examine associations between intakes of dietary fiber overall and by food source and risk of advanced and aggressive forms of PC. DESIGN: Pooled analysis of the primary data in 15 cohorts in three continents. Baseline dietary fiber intake was assessed using a validated food frequency questionnaire or diet history in each study...
April 15, 2024: Journal of the Academy of Nutrition and Dietetics
https://read.qxmd.com/read/38634046/genetic-ancestry-and-radical-prostatectomy-findings-in-hispanic-latino-patients
#5
JOURNAL ARTICLE
Natalia L Acosta-Vega, Rodolfo Varela, Jorge Andrés Mesa, Jone Garai, Alberto Gómez-Gutiérrez, Silvia J Serrano-Gómez, Jovanny Zabaleta, María Carolina Sanabria-Salas, Alba L Combita
BACKGROUND: African ancestry is a known factor associated with the presentation and aggressiveness of prostate cancer (PC). Hispanic/Latino populations exhibit varying degrees of genetic admixture across Latin American countries, leading to diverse levels of African ancestry. However, it remains unclear whether genetic ancestry plays a role in the aggressiveness of PC in Hispanic/Latino patients. We explored the associations between genetic ancestry and the clinicopathological data in Hispanic/Latino PC patients from Colombia...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38633832/patient-centred-pathology-reporting-improves-patient-experience-and-understanding-of-disease-in-prostate-cancer-care
#6
JOURNAL ARTICLE
Haidar Al Saffar, Alice Thomson, Jo-Lynn S Tan, Qiwei Wang, Emma Birch, Samantha Koschel, Elizabeth Medhurst, Dale Jobson, Sean Ong, Daniel A Moon, Declan Murphy, Nathan Lawrentschuk
INTRODUCTION AND OBJECTIVES: Patient-centred (PC) and holistic care improves patient satisfaction and health outcomes. We sought to investigate the benefit of utilising a PC pathology report in patients undergoing radical prostatectomy (RP) for prostate cancer (PCa). Our study aimed to evaluate and compare patient understanding of their PCa diagnosis after RP, upon receiving either a standard histopathology report or a personalised and PC report (PCR). Moreover, we evaluated knowledge retention at 4 weeks after the initial consultation...
April 2024: BJUI compass
https://read.qxmd.com/read/38633829/the-impact-of-pre-biopsy-mri-and-additional-testing-on-prostate-cancer-screening-outcomes-a-rapid-review
#7
REVIEW
Abel Tesfai, Natalia Norori, Thomas A Harding, Yui Hang Wong, Matthew David Hobbs
OBJECTIVE: This work aims to examine the latest evidence on the impact of pre-biopsy MRI, in addition to prostate-specific antigen (PSA) testing, on health outcomes and quality of life. METHODS: We conducted a literature search including PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) databases, with a limited scan of (i) guidelines and (ii) references from trial reports, from January 2005 to 25th January 2023. Two independent reviewers selected randomised controlled trials (RCT) and cohort studies which met our inclusion criteria...
April 2024: BJUI compass
https://read.qxmd.com/read/38623561/federated-attention-consistent-learning-models-for-prostate-cancer-diagnosis-and-gleason-grading
#8
JOURNAL ARTICLE
Fei Kong, Xiyue Wang, Jinxi Xiang, Sen Yang, Xinran Wang, Meng Yue, Jun Zhang, Junhan Zhao, Xiao Han, Yuhan Dong, Biyue Zhu, Fang Wang, Yueping Liu
Artificial intelligence (AI) holds significant promise in transforming medical imaging, enhancing diagnostics, and refining treatment strategies. However, the reliance on extensive multicenter datasets for training AI models poses challenges due to privacy concerns. Federated learning provides a solution by facilitating collaborative model training across multiple centers without sharing raw data. This study introduces a federated attention-consistent learning (FACL) framework to address challenges associated with large-scale pathological images and data heterogeneity...
December 2024: Computational and Structural Biotechnology Journal
https://read.qxmd.com/read/38622987/the-prevalence-and-clinical-significance-of-her2-expression-in-prostate-adenocarcinoma
#9
JOURNAL ARTICLE
Fayez Estephan, Coen J Lap, Jeff Banagan, Martha Antonio, Shanshan Liu, Guoqing Diao, Alexandra Zara Rozalen, Rithika Rajendran, Steven Krasnow, Ramesh Subrahmanyam, Victor E Nava, Maneesh Jain
AIMS: Abnormalities in HER2 are well-established oncogenic drivers and are approved therapeutic targets in various malignancies. Prior studies evaluating HER2 expression in prostate cancer (PCa) have yielded variable results. Most of these studies used immunohistochemistry scoring systems based on breast cancer data. The goal of this study was to determine the prevalence and clinical significance of HER2 expression using a scoring system that better reflects the HER2 staining pattern observed in PCa...
December 2023: Annals of Diagnostic Pathology
https://read.qxmd.com/read/38617934/-1-h-nmr-based-urine-metabolomics-of-prostate-cancer-and-benign-prostatic-hyperplasia
#10
JOURNAL ARTICLE
Mohammed Zniber, Tarja Lamminen, Pekka Taimen, Peter J Boström, Tan-Phat Huynh
BACKGROUND: Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are prevalent conditions affecting a significant portion of the male population, particularly with advancing age. Traditional diagnostic methods, such as digital rectal examination (DRE) and prostate-specific antigen (PSA) tests, have limitations in specificity and sensitivity, leading to potential overdiagnosis and unnecessary biopsies. SIGNIFICANCE: This study explores the effectiveness of 1 H NMR urine metabolomics in distinguishing PCa from BPH and in differentiating various PCa grades, presenting a non-invasive diagnostic alternative with the potential to enhance early detection and patient-specific treatment strategies...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38608782/long-term-evaluation-of-optimized-gleason-grading-in-a-large-cohort-of-men-with-prostate-cancer-in-canada
#11
JOURNAL ARTICLE
Michel Wissing, Fadi Brimo, Ginette McKercher, Eleonora Scarlata, Fred Saad, Michel Carmel, Louis Lacombe, Bernard Têtu, Nadia Ekindi-Ndongo, Mathieu Latour, Dominique Trudel, Simone Chevalier, Armen Aprikian
OBJECTIVES: To evaluate the International Society of Urological Pathology (ISUP) 5-tier grade grouping (GG) system of prostate cancers as well as previously proposed optimizations. PATIENTS AND METHODS: The PROCURE biobank is a prospective cohort study of patients with localized prostate cancer who underwent radical prostatectomy in Quebec province between 2005 and 2013. Surgical specimens were graded by experienced genitourinary pathologists using 2019 ISUP criteria...
April 10, 2024: Human Pathology
https://read.qxmd.com/read/38602755/-mechanism-study-on-the-effect-of-androgen-antagonism-in-prostate-cancer
#12
JOURNAL ARTICLE
Xu Song, Qiang Song, Rong Wang, Qing-Jun Zuo, Zhi-Yuan Zhang
OBJECTIVE: To explore the mechanism of tetrahydroxynonene (4-HNE) in the androgen antagonistic effect of prostate cancer through the androgen receptor (AR) - mitogen activated protein kinase (MAPK) signaling pathway. METHOD: Prostate cancer LNCaP cells were divided into wild-type group (NC, control group) and transfection group. The transfection group was further divided into empty vector transfection group (NC-L7 group) and GSTA4 gene transfection group (A0718, GSTA4-OE group)...
May 2023: Zhonghua Nan Ke Xue, National Journal of Andrology
https://read.qxmd.com/read/38590967/real-world-retrospective-study-of-prostate-specific-antigen-and-safety-assessment-with-darolutamide-plus-androgen-deprivation-therapy-for-metastasis-hormone-sensitive-prostate-cancer
#13
JOURNAL ARTICLE
Jia Liu, Shenghan Wang, Yong Yang, Shuo Wang, Davide Campobasso, Yu Guang Tan, Qiang Gao, Lin Yang, Yudong Cao, Yongpeng Ji, Peng Du, Bao Zhang
BACKGROUND: ARASENS has demonstrated the efficacy and safety for darolutamide (DARO) with androgen deprivation therapy (ADT) plus docetaxel in metastasis hormone-sensitive prostate cancer (mHSPC). There is a lack of reports for DARO with ADT in mHSPC though the regimen is used in clinical from time to time. Moreover, recent studies have supported the importance of early and rapid prostate-specific antigen (PSA) reduction, which correlates with reduced disease progression and improved survival in patients with mHSPC...
March 31, 2024: Translational Andrology and Urology
https://read.qxmd.com/read/38587980/micro-ultrasound-for-the-detection-of-clinically-significant-prostate-cancer-in-biopsy-naive-men-with-negative-mri
#14
JOURNAL ARTICLE
Patrick Albers, Jacob Bennett, Moira Evans, Ella St Martin, Betty Wang, Stacey Broomfield, Anaïs Medina Martín, Wendy Tu, Christopher Fung, Adam Kinnaird
INTRODUCTION: Despite a negative magnetic resonance imaging (MRI), some patients may still harbor clinically significant prostate cancer (csPCa, Gleason grade group ≥2). High-resolution micro-ultrasound (microUS) is a novel imaging technology that could visualize csPCa that is missed by MRI. METHODS: This retrospective review included 1011 consecutive patients biopsied between September 2021 and July 2023 in Alberta, Canada. Among them were 103 biopsy-naive patients with negative MRI (Prostate Imaging Reporting & Data System [PI-RADS] ≤2) undergoing microUS-informed prostate biopsy (n=56) scored using Prostate Risk Identification Using Micro-ultrasound (PRI-MUS) or standard transrectal ultrasound prostate biopsy (n=47)...
April 2, 2024: Canadian Urological Association Journal
https://read.qxmd.com/read/38581590/expected-impact-of-mri-targeted-biopsy-interreader-variability-among-uropathologists-on-proscreen-prostate-cancer-screening-trial-a-pre-trial-validation-study
#15
JOURNAL ARTICLE
Ronja Hietikko, Tuomas Mirtti, Tuomas P Kilpeläinen, Teemu Tolonen, Anne Räisänen-Sokolowski, Stig Nordling, Jill Hannus, Marita Laurila, Kimmo Taari, Teuvo L J Tammela, Reija Autio, Kari Natunen, Anssi Auvinen, Antti Rannikko
PURPOSE: Prostate cancer (PCa) histology, particularly the Gleason score, is an independent prognostic predictor in PCa. Little is known about the inter-reader variability in grading of targeted prostate biopsy based on magnetic resonance imaging (MRI). The aim of this study was to assess inter-reader variability in Gleason grading of MRI-targeted biopsy among uropathologists and its potential impact on a population-based randomized PCa screening trial (ProScreen). METHODS: From June 2014 to May 2018, 100 men with clinically suspected PCa were retrospectively selected...
April 6, 2024: World Journal of Urology
https://read.qxmd.com/read/38581198/prostate-specific-antigen-screening-and-15-year-prostate-cancer-mortality-a-secondary-analysis-of-the-cap-randomized-clinical-trial
#16
JOURNAL ARTICLE
Richard M Martin, Emma L Turner, Grace J Young, Chris Metcalfe, Eleanor I Walsh, J Athene Lane, Jonathan A C Sterne, Sian Noble, Peter Holding, Yoav Ben-Shlomo, Naomi J Williams, Nora Pashayan, Mai Ngoc Bui, Peter C Albertsen, Tyler M Seibert, Anthony L Zietman, Jon Oxley, Jan Adolfsson, Malcolm D Mason, George Davey Smith, David E Neal, Freddie C Hamdy, Jenny L Donovan
IMPORTANCE: The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality at a median 10-year follow-up (primary outcome), but the long-term effects of PSA screening on prostate cancer mortality remain unclear. OBJECTIVE: To evaluate the effect of a single invitation for PSA screening on prostate cancer-specific mortality at a median 15-year follow-up compared with no invitation for screening...
April 6, 2024: JAMA
https://read.qxmd.com/read/38580670/the-influence-of-gleason-score%C3%A2-%C3%A2-%C3%A2-6-histology-on-the-outcome-of-high-risk-localized-prostate-cancer-after-modern-radiotherapy
#17
JOURNAL ARTICLE
Hideya Yamazaki, Gen Suzuki, Koji Masui, Norihiro Aibe, Takuya Kimoto, Kei Yamada, Koji Okihara, Fumiya Hongo, Masayoshi Okumi, Takumi Shiraishi, Atsuko Fujihara, Ken Yoshida, Satoaki Nakamura, Takashi Kato, Yasutoshi Hashimoto, Haruumi Okabe
We aimed to retrospectively review outcomes in patients with high-risk prostate cancer and a Gleason score ≤ 6 following modern radiotherapy. We analyzed the outcomes of 1374 patients who had undergone modern radiotherapy, comprising a high-risk low grade [HRLG] group (Gleason score ≤ 6; n = 94) and a high-risk high grade [HRHG] group (Gleason score ≥ 7, n = 1125). We included 955 patients who received brachytherapy with or without external beam radio-therapy (EBRT) and 264 who received modern EBRT (intensity-modulated radiotherapy [IMRT] or stereotactic body radiotherapy [SBRT])...
April 5, 2024: Scientific Reports
https://read.qxmd.com/read/38578393/novel-clinical-risk-calculator-for-improving-cancer-predictability-of-mpmri-fusion-biopsy-in-prostates
#18
JOURNAL ARTICLE
Anthony Bruccoliere, Vivie Tran, Naseem Helo, Abdul Awal, Stephanie Stroever, Werner T W de Riese
PURPOSE: Prostate Imaging-Reporting and Data System (PI-RADS) assists in evaluating lesions on multiparametric magnetic resonance imaging (mpMRI), but there are still ongoing efforts in improving the predictive value for the presence of clinically significant PCa (csPCa) with a Gleason grade group ≥ 2 on Fusion-Biopsy. This pilot study intends to propose an easily implementable method for augmenting predictability of csPCa for PI-RADS. METHODS: A cohort of 151 consecutive patients underwent mpMRI Fusion and random US Biopsy as a result of having at least one PI-RADS lesion grade 3-5 between January 1, 2019 and December 31, 2022...
April 5, 2024: International Urology and Nephrology
https://read.qxmd.com/read/38578052/discrepancies-in-gleason-score-between-needle-core-biopsy-and-radical-prostatectomy-specimens-with-correlation-between-clinical-and-pathological-staging
#19
JOURNAL ARTICLE
Vikram Singh, Kartik Sharma, Mahendra Singh, Shashank Shekhar Tripathi, Deepak Prakash Bhirud, Rahul Jena, Shiv Charan Navriya, Gautam Ram Choudhary, Arjun Singh Sandhu
BACKGROUND: The studies have shown that GS given after assessment of the entire prostate gland on the radical prostatectomy specimen may differ from GS given after examination of a small sample from needle core biopsy. We conducted this study to assess discrepancies in the Gleason score between NCB and RP specimens and to find out the correlation between the clinical stage and pathological stage. METHODS: The study included 174 patients with carcinoma prostate which underwent robotic-assisted radical prostatectomy (RARP)...
April 5, 2024: Urologia
https://read.qxmd.com/read/38577575/develop-prediction-model-to-help-forecast-advanced-prostate-cancer-patients-prognosis-after-surgery-using-neural-network
#20
JOURNAL ARTICLE
Shanshan Li, Siyu Cai, Jinghong Huang, Zongcheng Li, Zhengyu Shi, Kai Zhang, Juan Jiao, Wei Li, Yuanming Pan
BACKGROUND: The effect of surgery on advanced prostate cancer (PC) is unclear and predictive model for postoperative survival is lacking yet. METHODS: We investigate the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, to collect clinical features of advanced PC patients. According to clinical experience, age, race, grade, pathology, T, N, M, stage, size, regional nodes positive, regional nodes examined, surgery, radiotherapy, chemotherapy, history of malignancy, clinical Gleason score (composed of needle core biopsy or transurethral resection of the prostate specimens), pathological Gleason score (composed of prostatectomy specimens) and prostate-specific antigen (PSA) are the potential predictive variables...
2024: Frontiers in Endocrinology
keyword
keyword
98250
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.